Eric H. Rubin

Generating author description...

All published works

Action	Title	Year	Authors
+	Data from Finding the Right Dose for Cancer Therapeutics—Can We Do Better?	2023	Eric H. Rubin Keaven M. Anderson
+	Data from Finding the Right Dose for Cancer Therapeutics—Can We Do Better?	2023	Eric H. Rubin Keaven M. Anderson
+	Adaptive phase 2/3 designs for oncology drug development – Time to hedge	2022	Cong Chen Eric H. Rubin
+ PDF Chat	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials	2022	Pralay Mukhopadhyay Jiabu Ye Keaven M. Anderson Satrajit Roychoudhury Eric H. Rubin Susan Halabi Richard J. Chappell
+	Optimal two-stage designs for exploratory basket trials	2019	Heng Zhou Fang Liu Cai Wu Eric H. Rubin Vincent L. Giranda Cong Chen
+ PDF Chat	Challenges with Novel Clinical Trial Designs: Master Protocols	2019	Michael Cecchini Eric H. Rubin Gideon M. Blumenthal Kassa Ayalew Howard A. Burris Michele K. Russell-Einhorn Hildy Dillon H. Kim Lyerly Gregory H. Reaman Scott A. Boerner
+ PDF Chat	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology	2018	Brian P. Hobbs Pedro C. Barata Yada Kanjanapan Channing J. Paller Jane Perlmutter Gregory R. Pond Tatiana M. Prowell Eric H. Rubin Lesley Seymour Nolan A. Wages
+	Abstract 4759: Designing clinical trials in tumor indications with a positive signal in phase 1	2018	Cong Chen Keaven M. Anderson Devan V. Mehrotra Eric H. Rubin Archie Tse
+	Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years	2018	Pedro Barata Brian P. Hobbs Brian I. Rini Channing J. Paller Daniel P. Normolle Elizabeth Garrett‐Mayer Eric H. Rubin Gary L. Rosner Gregory R. Pond Jane Perlmutter
+	Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop	2017	Paul G. Kluetz Bindu Kanapuru Steven J. Lemery Laura Lee Johnson Mallorie H. Fiero Karen Arscott Yolanda Barbáchano Ethan Basch Michelle Campbell Joseph C. Cappelleri
+	A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development	2017	Cong Chen Keaven M. Anderson Devan V. Mehrotra Eric H. Rubin Archie Tse
+	Abstract 3596: How many tumor indications should be initially studied in clinical development of next-generation immunotherapies	2017	Cong Chen Qiqi Deng Linchen He Devan V. Mehrotra Eric H. Rubin Robert A. Beckman
+	How many tumor indications should be initially screened in development of next generation immunotherapies?	2017	Cong Chen Qiqi Deng Linchen He Devan V. Mehrotra Eric H. Rubin Robert A. Beckman
+	Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy	2016	Lei Nie Eric H. Rubin Nitin Mehrotra José Cirı́aco Pinheiro Laura L. Fernandes Amit Roy Stuart Bailey Dinesh P. de Alwis
+ PDF Chat	Advancing Clinical Trials to Streamline Drug Development	2015	Susan E. Bates Donald A. Berry Sanjeeve Balasubramaniam Stuart Bailey Patricia LoRusso Eric H. Rubin
+ PDF Chat	Comment	2015	Anastasia Ivanova Keaven M. Anderson Gary L. Rosner Eric H. Rubin
+	University of Pennsylvania 5th annual conference on statistical issues in Clinical Trials: Emerging statistical issues in biomarker validation (afternoon session)	2013	Eric H. Rubin Lisa M. LaVange Victor DeGruttola
+	4 Response-Adaptive Randomized Early Clinical Trials – can BATTLE and SPYs help in co-development of cancer drugs and diagnostics?	2012	Eric H. Rubin
+	Drug development and clinical trials—the path to an approved cancer drug	2012	Eric H. Rubin D. Gary Gilliland
+ PDF Chat	Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials	2012	Donald A. Berry Roy S. Herbst Eric H. Rubin
+ PDF Chat	Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics	2011	Howard I. Scher S Nasso Eric H. Rubin Richard H. Simon
+	Is there a therapeutic benefit for patients participating in modern phase I trials?	2011	Mark N. Stein Anderson Tan Janice M. Mehnert Darlene Gibbon Robert S. DiPaola R. Moss Elizabeth Poplin Eric H. Rubin Biren Saraiya M. P. Kane
+ PDF Chat	Finding the Right Dose for Cancer Therapeutics—Can We Do Better?	2010	Eric H. Rubin Keaven M. Anderson
+	Phase I Trial Design and Methodology for Anticancer Drugs	2004	Patrick V. Acevedo Deborah Toppmeyer Eric H. Rubin

Common Coauthors

Coauthor	Papers Together
Keaven M. Anderson	7
Cong Chen	4
Devan V. Mehrotra	4
Gary L. Rosner	3
Elizabeth Garrett‐Mayer	2
Robert A. Beckman	2
Jane Perlmutter	2
Linchen He	2
Lillian L. Siu	2
Stuart Bailey	2
Cong Chen	2
David S. Hong	2
Nolan A. Wages	2
Tatiana M. Prowell	2
Patricia LoRusso	2
Brian P. Hobbs	2
Donald A. Berry	2
Channing J. Paller	2
Gregory R. Pond	2
Archie Tse	2
Lesley Seymour	2
Timothy A. Yap	2
Qiqi Deng	2
P. Kirin	1
Michelle Campbell	1
H. Kim Lyerly	1
Sheetal Patel	1
Jiabu Ye	1
Anastasia Ivanova	1
Brian I. Rini	1
Sanjeeve Balasubramaniam	1
Patrick Scott	1
M. LaRosiliere	1
Kassa Ayalew	1
Anna Rydén	1
Percy Ivy	1
Victor DeGruttola	1
Daniel O’Connor	1
David Cella	1
Gregory H. Reaman	1
Lori M. Minasian	1
Corneel Coens	1
M. P. Kane	1
Michele K. Russell-Einhorn	1
Charles S. Cleeland	1
Galina Velikova	1
Cai Wu	1
Darlene Gibbon	1
Deborah Toppmeyer	1
Roy S. Herbst	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman	5
+ PDF Chat	Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients	2005	Boris Freidlin Richard Simon	4
+ PDF Chat	Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics	2011	Howard I. Scher S Nasso Eric H. Rubin Richard H. Simon	3
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	3
+	Cancer phase I clinical trials: efficient dose escalation with overdose control	1998	James S. Babb André Rogatko Shelemyahu Zacks	3
+ PDF Chat	Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer	2007	Theodore Karrison Michael L. Maitland Walter M. Stadler Mark J. Ratain	3
+	Dose-finding in phase I clinical trials based on toxicity probability intervals	2007	Yuan Ji Yisheng Li B. Nebiyou Bekele	3
+	How many tumor indications should be initially screened in development of next generation immunotherapies?	2017	Cong Chen Qiqi Deng Linchen He Devan V. Mehrotra Eric H. Rubin Robert A. Beckman	3
+	The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research	2015	Donald A. Berry	2
+	Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials	2014	René Bruno François Mercier Laurent Claret	2
+	Surrogate End Points in Clinical Trials: Are We Being Misled?	1996	Thomas R. Fleming	2
+	A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development	2017	Cong Chen Keaven M. Anderson Devan V. Mehrotra Eric H. Rubin Archie Tse	2
+	Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples	2016	Lindsay A. Renfro Daniel J. Sargent	2
+ PDF Chat	Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse	2010	Rajul K. Jain J. Jack Lee David S. Hong Maurie Markman Jing Gong Aung Naing Jennifer J. Wheler Razelle Kurzrock	2
+ PDF Chat	Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials	2012	Donald A. Berry Roy S. Herbst Eric H. Rubin	2
+	Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study	2016	Cong Chen Xiaoyun Li Shuai Yuan Zoran Antonijevic Rasika Kalamegham Robert A. Beckman	2
+ PDF Chat	The Cross-Validated Adaptive Signature Design	2010	Boris Freidlin Wenyu Jiang Richard Simon	2
+	The Bayesian basket design for genomic variant-driven phase II trials	2016	Richard Simon Susan Geyer Jyothi Subramanian Sameek Roychowdhury	2
+	Integrating predictive biomarkers and classifiers into oncology clinical development programmes	2011	Robert A. Beckman Jason Clark Cong Chen	2
+ PDF Chat	Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both	2017	Janet Woodcock Lisa M. LaVange	2
+ PDF Chat	Outcome-Adaptive Randomization: Is It Useful?	2010	Edward L. Korn Boris Freidlin	2
+	Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker	2016	RA Beckman Zoran Antonijevic Rasika Kalamegham C Chen	2
+	Adaptive clinical trials in oncology	2011	Donald A. Berry	2
+	Designed Extension of Studies Based on Conditional Power	1995	Michael A. Proschan Sally Hunsberger	1
+	Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline	1999	John A. Lewis	1
+ PDF Chat	Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves	2012	Patricia Guyot A. E. Ades Mario JNM Ouwens Nicky J. Welton	1
+ PDF Chat	Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials	2013	Scott Berry Kristine Broglio Susan Groshen Donald A. Berry	1
+	Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development	2009	Cong Chen Robert A. Beckman	1
+ PDF Chat	Small sample size is not the real problem	2013	Peter Bacchetti	1
+	Dose Finding Using the Biased Coin Up‐and‐Down Design and Isotonic Regression	2002	Mario Stylianou Nancy Flournoy	1
+	Practical Bayesian Guidelines for Phase IIB Clinical Trials	1994	Peter F. Thall Richard H. Simon	1
+	Practical modifications of the continual reassessment method for phase i cancer clinical trials	1994	Douglas E. Faries	1
+	Redefining the primary objective of phase I oncology trials	2014	Mark J. Ratain	1
+	Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug Development	1990	Jerry M. Collins Charles K. Grieshaber Bruce A. Chabner	1
+	Genomic Classifier for Patient Enrichment: Misclassification and Type I Error Issues in Pharmacogenomics Noninferiority Trial	2010	Sue‐Jane Wang Hung Hung Robert T. O’Neill	1
+ PDF Chat	Decision-theoretic designs for small trials and pilot studies: A review	2015	Siew Wan Hee Thomas Hamborg Simon Day Jason Madan Frank Miller Martin Posch Sarah Zohar Nigel Stallard	1
+	Modeling Survival Data: Extending the Cox Model	2000	Terry M. Therneau Patricia M. Grambsch	1
+	A sequential phase II/III trial for binary outcomes	1990	Barry E. Storer	1
+	A class of rank test procedures for censored survival data	1982	David P. Harrington Thomas R. Fleming	1
+ PDF Chat	Simple, Defensible Sample Sizes Based on Cost Efficiency	2008	Peter Bacchetti Charles E. McCulloch Mark R. Segal	1
+	Using Patient-Initiated Study Participation in the Development of Evidence for Personalized Cancer Therapy	2011	Laurie Fenton Ambrose Jamie Freedman Kenneth H. Buetow Stephen Friend Richard L. Schilsky	1
+	A REDUCTION FORMULA FOR NORMAL MULTIVARIATE INTEGRALS	1954	R. L. Plackett	1
+	Inference on treatment effects for targeted clinical trials under enrichment design	2009	Jen‐pei Liu Jr‐Rung Lin Shein‐Chung Chow	1
+	Statistics: A Bayesian Perspective	1995	Donald A. Berry	1
+ PDF Chat	A predictive probability design for phase II cancer clinical trials	2008	J. Jack Lee Diane D. Liu	1
+ PDF Chat	Critical aspects of the Bayesian approach to phase I cancer trials	2008	Beat Neuenschwander Michael Branson Thomas Gsponer	1
+ PDF Chat	Trends in the Use and Role of Biomarkers in Phase I Oncology Trials	2007	Bernardo H. L. Goulart Jeffrey W. Clark Homer Pien Thomas G. Roberts Stan N. Finkelstein Bruce A. Chabner	1
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon	1
+	Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration	2010	Werner Brannath Hans Ulrich Burger Ekkehard Glimm Nigel Stallard Marc Vandemeulebroecke Gernot Wassmer	1
+	Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development	2009	Brenda Gaydos Keaven M. Anderson Donald A. Berry Nancy Burnham Christy Chuang‐Stein Jennifer Dudinak Parvin Fardipour Paul Gallo Sam Givens Roger Lewis	1